Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases by Nagumo, K. et al.
Cys34-Cysteinylated Human Serum Albumin Is a
Sensitive Plasma Marker in Oxidative Stress-Related
Chronic Diseases
Kohei Nagumo1, Motohiko Tanaka2, Victor Tuan Giam Chuang3, Hiroko Setoyama2, Hiroshi Watanabe1,4,
Naoyuki Yamada5, Kazuyuki Kubota5, Motoko Tanaka6, Kazutaka Matsushita6, Akira Yoshida7,
Hideaki Jinnouchi7, Makoto Anraku8, Daisuke Kadowaki1,4, Yu Ishima1,4, Yutaka Sasaki2,
Masaki Otagiri8,9, Toru Maruyama1,4*
1 Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Chuo-ku, Kumamoto, Japan, 2 Department of Gastroenterology
and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Chuo-ku, Kumamoto, Japan, 3 School of Pharmacy, Curtin Health Innovation Research
Institute, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia, 4 Center for Clinical Pharmaceutical Science, Kumamoto University, Chuo-ku,
Kumamoto, Japan, 5 Institute of Innovation, Ajinomoto Co., Inc., Kawasaki-ku, Kawasaki, Japan, 6 Department of Nephrology, Akebono Clinic, Minami-Ku, Kumamoto,
Japan, 7 Jinnouchi Clinic, Diabetes Care Center, Chuo-ku, Kumamoto, Japan, 8 Faculty of Pharmaceutical Sciences, Sojo University, Nishi-ku, Kumamoto, Japan, 9 DDS
Research Institute, Sojo University, Nishi-ku, Kumamoto, Japan
Abstract
The degree of oxidized cysteine (Cys) 34 in human serum albumin (HSA), as determined by high performance liquid
chromatography (HPLC), is correlated with oxidative stress related pathological conditions. In order to further characterize
the oxidation of Cys34-HSA at the molecular level and to develop a suitable analytical method for a rapid and sensitive
clinical laboratory analysis, the use of electrospray ionization time-of-flight mass spectrometer (ESI-TOFMS) was evaluated. A
marked increase in the cysteinylation of Cys34 occurs in chronic liver and kidney diseases and diabetes mellitus. A
significant positive correlation was observed between the Cys-Cys34-HSA fraction of plasma samples obtained from 229
patients, as determined by ESI-TOFMS, and the degree of oxidized Cys34-HSA determined by HPLC. The Cys-Cys34-HSA
fraction was significantly increased with the progression of liver cirrhosis, and was reduced by branched chain amino acids
(BCAA) treatment. The changes in the Cys-Cys34-HSA fraction were significantly correlated with the alternations of the
plasma levels of advanced oxidized protein products, an oxidative stress marker for proteins. The binding ability of
endogenous substances (bilirubin and tryptophan) and drugs (warfarin and diazepam) to HSA purified from chronic liver
disease patients were significantly suppressed but significantly improved by BCAA supplementation. Interestingly, the
changes in this physiological function of HSA in chronic liver disease were correlated with the Cys-Cys34-HSA fraction. In
conclusion, ESI-TOFMS is a suitable high throughput method for the rapid and sensitive quantification of Cys-Cys34-HSA in a
large number of samples for evaluating oxidative stress related chronic disease progression or in response to a treatment.
Citation: Nagumo K, Tanaka M, Chuang VTG, Setoyama H, Watanabe H, et al. (2014) Cys34-Cysteinylated Human Serum Albumin Is a Sensitive Plasma Marker in
Oxidative Stress-Related Chronic Diseases. PLoS ONE 9(1): e85216. doi:10.1371/journal.pone.0085216
Editor: Rizwan H. Khan, Aligarh Muslim University, India
Received October 22, 2013; Accepted November 29, 2013; Published January 8, 2014
Copyright:  2014 Nagumo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: tomaru@gpo.kumamoto-u.ac.jp
Introduction
Post-translationally modified proteins can be used as biomarkers
for the diagnosis of diseases or for the assessment of treatment
responses. A prime example of this is the quantification of glycated
hemoglobin and glycoalbumin for the diagnosis and treatment of
diabetes mellitus [1,2]. Recent studies have demonstrated an
association between oxidative stress and the development of
chronic diseases. There is growing interest in developing
diagnostic tools to monitor the extent of oxidative damage in
tissues or organs, and the use of novel anti-oxidants for the
treatment or prevention of such oxidative stress-related diseases
[3–5]. However, at present, a rapid and sensitive clinical
laboratory testing method for the rapid assessment of oxidative
stress in humans is lacking.
Era’s group and our laboratory have both developed a high
performance liquid chromatography (HPLC) method to monitor
the redox status of cysteine (Cys) 34 in human serum albumin
(HSA) (Figure 1) [6,7]. Since the redox status of thiol (SH) groups
sensitively reflects the oxidation-reduction status of its surrounding
environment, this HPLC analytical method has been shown to be
useful for assessing the level of oxidative stress in diseased states
and for evaluating the anti-oxidative activity of a therapeutic agent
[8–11].
Previous studies of Cys34 have shown that Cys34 can be
modified by treatment with cysteine, glutathione, homocysteine or
drugs that contain a SH group. Cys34 can also be oxidized to a
sulfonic acid and a sulfinic acid, but information on the degree of
each modified form of Cys34 under diseased conditions is not
available [12–16]. Unfortunately, the HPLC analytical method
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does not provide any molecular structural information regarding
the oxidized form of Cys34. Therefore, we attempted to establish
an analytical method that allows the quantitative and qualitative
evaluation of the redox state of Cys34 with a high degree of
sensitivity using electrospray ionization time-of-flight mass spec-
trometer (ESI-TOFMS) to analyze HSA that is cysteinylated at
Cys34 (Cys-Cys34-HSA) in vitro using plasma samples obtained
from healthy subjects [17,18]. Moreover, recent analyses using
ESI-TOFMS indicate that a significant amount of Cys-Cys34-
HSA is present in the amniotic fluid of patients with gestational
diabetes mellitus and in the plasma of dialysis patients [19,20]. If
Cys-Cys34-HSA accounts for the majority of the oxidized forms of
Cys34, the fraction of Cys-Cys34-HSA, as estimated by ESI-
TOFMS should correspond to the degree of oxidized Cys34-HSA
determined by HPLC reported in previous studies, and this may
permit the fraction of Cys-Cys34-HSA to be used as a novel
marker for oxidative stress in the blood circulation.
Nevertheless, correlations between the fraction of Cys-
Cys34-HSA determined by ESI-TOFMS and the degree
of oxidized Cys34-HSA determined by HPLC have not been
reported. Furthermore, the impact of the cysteinylation of
Cys34 on HSA functions in a diseased state, and the




Blue Sepharose 6 Fast Flow was from GE Healthcare (Tokyo,
Japan). Potassium warfarin (Eisai Co., Tokyo, Japan), L-trypto-
phan (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and
diazepam (Nippon Roche K.K., Tokyo, Japan) were obtained. All
other chemicals were of the highest grade commercially available,
and all solutions were prepared using deionized and distilled
water.
Figure 1. The structure of HSA. Superposition of the Cys34 and
the location of two major ligand binding sites, Site I and II are
shown.
doi:10.1371/journal.pone.0085216.g001
Table 1. General characteristics of the study participants.
Healthy Subjects Patients
Chronic Liver Disease Chronic Kidney Disease (HD) Diabetes Mellitus
Category N = 9 N = 139 N = 38 N = 52
Gender (M/F) 6/3 60/79 20/18 21/31
Age (years) 61.464.4 57.4615.0 58.6616.1 59.0616.1
Albumin (g/dl) N/A 3.360.5 N/A N/A
Bilirubin (mg/dL) N/A 1.561.3 N/A N/A
BUN (mg/dL) N/A N/A 63.6611.8 N/A
SCr (mg/dL) N/A N/A 11.261.9 N/A
HbA1c (%) N/A N/A N/A 7.961.6
Mean 6 SD value are shown. BUN; blood urea nitrogen, SCr; serum creatinine, HD; hemodialysis.
doi:10.1371/journal.pone.0085216.t001
Figure 2. Deconvoluted ESI-TOFMS spectra of HSA. (A) Spectrum
of HSA from healthy subject. (B) Spectrum of HSA from patient with
chronic liver disease. (C) Spectrum of HSA from the same patient that
(B) after DTT treatment. The peaks correspond to the following: (a) Asp-
Ala truncation from N-terminal of HSA, (b) Leu truncation from C-
terminal of HSA, (c) reduced HSA, (d) Cys-Cys34-HSA, (e) glycated HSA
and (f) glycated Cys-Cys34-HSA.
doi:10.1371/journal.pone.0085216.g002
ESI-TOFMS Quantification of Cysteinylated HSA
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Ethics statement
The study was approved by the institutional review board of
Kumamoto University, and each of the institutional review boards
of the hospitals where samples were collected (‘‘Ethics Committee
of the Hospital Akebono Clinic, ‘‘Ethics Committee of the
Hospital Jinnouchi Clinic’’). All samples were obtained with
written informed consent reviewed by the ethical board of the
corresponding hospital.
Clinical study of the correlation of Cys-Cys34-HSA and
oxidized Cys34-HSA
9 mL blood samples were collected from individual study
subjects and the samples were subjected to only one freeze thaw
cycle, based on our previous work [18]. The collected blood was
immediately diluted with 0.5 M sodium citrate buffer (pH 4.3) to
stabilize for reduced albumin. Each plasma fraction was separated
by centrifugation (4uC for 15 min, 2000 g). After collection,
plasma samples were stored at 280uC until batch analysis.
Chronic liver disease. 139 patients with liver cirrhosis who
had been admitted to the Kumamoto University Medical School
Hospital of Japan, between March 2011 and May 2013 were
enrolled in this study. The stratified Child-Pugh class was used to
estimate the severity of liver disease The liver cirrhosis patients
were divided into 3 groups according to their Child-Pugh
classification: Child-Pugh grade A (n = 79; 68.20612.88 yrs),
Child-Pugh grade B (n = 44; 62.71611.93 yrs), and Child-Pugh
grade C (n = 16; 54.7367.27 yrs) (Table 1).
Chronic kidney disease. 38 patients with chronic renal
failure who had been admitted to the Department of Nephrology
of the Akebono Clinic of Japan, between March 2011 and May
2012 were enrolled in this study (58.55616.06 yrs). End-stage
renal failure in hemodialysis (HD) patients were caused by
glomerulonephritis (n = 8), nephrosclerosis (n = 5) or diabetic
nephropathy (n = 14) (Table 1). At the time of their enrollment,
all of the HD patients were receiving regular bicarbonate HD
therapy (4 to 5 hours per session, 3 times per week) using high-flux
polysulfone hollow-fiber dialyzers.
Diabetes mellitus. 52 patients with type 2 diabetes who had
been admitted to the Jinnouchi Clinic, Diabetes Care Center of
Japan, between March 2011 and May 2013 were enrolled in
this study (58.98616.06 yrs) (Table 1). Eligible patients were
21–86 years old, HbA1C.7% and suffering from type 2 diabetes
for at least 1 year but no longer than 5 years.
Effect of branched-chain amino acid (BCAA) treatment on
Cys-Cys34-HSA in chronic liver disease patients. 60
patients with liver cirrhosis who had been admitted to the
Kumamoto University Hospital of Japan, between March 2011
and May 2012 were enrolled in this study. The study population
used for assessing the effect of BCAA treatment status is a sub-set
of the patient population used for chronic liver diseases. These
patients were given oral BCAA granules containing 952 mg of L-
isoleucine, 1904 mg of L-leucine and 1144 mg of L-valine
(LIVACTH Granules, AJINOMOTO PHARMACEUTICALS
CO., LTD., Tokyo, Japan) at 4.15 g/sachet three times a day
after meals. Plasma sample were collected at before, 3 and
5 months after treatment. The average albumin concentrations at
before, 3 and 5 months after BCAA treatment were 2.8560.48 g/
dl, 3.2160.43 g/dl and 3.3660.40 g/dl respectively. Plasma
samples from age and sex-matched nine healthy subjects as
controls were obtained from Kumamoto University Hospital
(Table 1).
Determination of the degree of oxidized Cys34-HSA by
HPLC
The SH redox status of HSA was determined with the HPLC
system reported previously [8]. Briefly, 5 mL of aliquots of plasma
were analyzed using a Shodex Asahipak ES-502N 7C column
(Showa Denko, Tokyo, Japan). From the HPLC profile, the
content of the oxidized form (HNA) and the un-oxidized form
(HMA) of HSA was estimated as the area of each fraction divided
Figure 3. Relationship between the Cys-Cys34-HSA fraction
(ESI-TOFMS) and the degree of oxidized Cys34-HSA (HPLC).
The measured samples were 229 patients with chronic disease
(including 139 patients with liver disease (circle), 38 patients with
kidney disease (square) and 52 patients with diabetes mellitus
(triangle)) (R2 = 0.9025, P,0.001).
doi:10.1371/journal.pone.0085216.g003
Figure 4. Effect of disease progression on the Cys-Cys34-HSA
fraction in chronic liver disease patients. The Cys-Cys34-HSA
fraction was measured by ESI-TOFMS. Values are expressed as mean 6
SD (n = 9–79). *P,0.05 as compared with healthy subjects, #P,0.05 as
compared with Child-Pugh Grade A, and 1P,0.05 as compared with
Child-Pugh Grade B.
doi:10.1371/journal.pone.0085216.g004
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by the total area of the plasma HSA peak. Using the levels of HNA
and HMA, the degree of oxidized Cys34-HSA, (HNA/(HNA +
HMA)) 6100, which is considered to be a reliable marker for the
extent of systematic oxidative damage in uremic patients was
estimated [10,21].
Solid phase extraction and ESI-TOFMS measurement of
plasma samples
5 mL of plasma was added to 495 mL of 50 mM sodium
phosphate buffer (pH 6.0). A solid phase extraction (SPE) column
(Bond Elute-C18 EWP 200 mg/3cc, Varian, Inc., CA) was
initialized with 10/90 water/acetonitrile containing 0.1% formic
acid, then equilibration was performed with water (1 mL). The
above-mentioned diluted plasma sample was applied to the
equilibrated SPE column. The column was washed with 10%
acetonitrile (2 mL) containing 0.1% formic acid, and albumin was
eluted with 90% acetonitrile containing 0.1% formic acid.
2 mL of eluent was flow injected into the ESI-TOFMS
(microTOFH; Bruker Daltonics Inc. USA) at a flow rate of
15 mL/min with 10/90 water/acetonitrile containing 0.1% formic
acid using the auto sampler of Ultimate 3000 (Dionex, Idstein,
Germany).
The data were acquired by the MicroTOFH software (Bruker-
Daltonics) and processed for Maxent deconvolution using
DataAnalysisH software (Bruker-Daltonics). The deconvolution
mass range was set to be from 66000 to 68000 Da. And the mass
peak of HSA and its modified molecules such as Cys-Cys34-HSA
or glycated HSA, was automatically assigned and converted to an
output text file using script with a resolving power of 10000 m/dm
and absolute intensity threshold of 1000. The fraction of Cys-
Cys34-HSA (%) was calculated by (Cys-Cys34-HSA/(Cys-Cys34-
HSA + reduced HSA)) 6100.
Purification of HSA from the plasma of chronic liver
disease patients
HSA was purified from plasma samples using a previously
reported method [21]. Briefly, HSA samples were isolated by Blue
Sepharose 6 Fast Flow column (GE HealthcareTokyo, Japan). The
samples were then dialyzed against deionized water for 48 h at
4uC, followed by lyophilization. The purity of the HSA samples
was at least 95%, as evidenced by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and native-
PAGE, respectively [21].
Figure 5. Change in the Cys-Cys34-HSA fraction and oxidative stress marker, AOPP, by BCAA treatment. (A) Change in the Cys-Cys34-
HSA fraction. The Cys-Cys34-HSA fraction was measured by ESI-TOFMS. (B) Change in plasma AOPP level. (C) Correlation between the Cys-Cys34-HSA
fraction and plasma AOPP level in chronic liver disease (n = 69). Values are expressed as mean 6 SD (n = 20). *P,0.01 as compared with healthy
subjects, #P,0.05 as compared with before treatment.
doi:10.1371/journal.pone.0085216.g005
ESI-TOFMS Quantification of Cysteinylated HSA
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Figure 6. Relationship between the Cys-Cys34-HSA fraction and the ligand unbound fraction in chronic liver disease patients. Effect
of disease progression on the unbound fraction of warfarin (A), bilirubin (B), diazepam (C) and L-tryptophan (D) to purified HSA. Effect of BCAA
treatment on the unbound fraction of warfarin (E), bilirubin (F), diazepam (G) and L-tryptophan (H) to purified HSA. Correlation between the Cys-
ESI-TOFMS Quantification of Cysteinylated HSA
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Determination of the unbound fraction of L-tryptophan,
warfarin or diazepam to purified HSA
The binding of L-tryptophan, warfarin or diazepam (12.5 mM)
to HSA (25 mM) purified from the plasma of chronic liver disease
patients and healthy subjects in 67 mM sodium phosphate buffer
(pH 7.4) was examined by ultrafiltration at 37uC. The ultrafiltra-
tion was carried out using a YM-30 ultrafiltration device (Amicon/
Millipore Inc., Bedford, MA, USA). HSA and the ligands were
dissolved in 67 mM sodium phosphate buffer (pH 7.4). Samples of
250 mL were centrifuged at 10,000 g at 37uC for 3 min. Free
(unbound) ligand concentrations in the filtrates were quantified by
HPLC [22–24].
Determination of the unbound fraction of bilirubin to
purified HSA
The unbound bilirubin concentrations were determined using a
modified horseradish peroxidase (HRP) assay [25]. 15 mM
bilirubin was added to 30 mL HSA purified from the plasma of
chronic liver disease patients and healthy subjects dissolved in
67 mM phosphate buffer (pH 7.4). 200 mL aliquots of the
bilirubin/HSA complexes were placed in a 96 well-plate and the
samples allowed to equilibrate for 20 min at 37uC. 10 mL of
freshly diluted 1.75 mM hydrogen peroxide was then added to
each well, followed by incubation for 3 min. The reaction was
initiated by adding 10 mL of 1 ng/mL HRP. The rate of oxidative
destruction of the unbound bilirubin was monitored by the
reduction in the absorbance of the mixture at 450 nm for 10 min.
The concentrations of unbound bilirubin were determined by
extrapolating the rate of oxidation of bilirubin to a standard curve
prepared by plotting the oxidation rate versus the concentration of
bilirubin. It was assumed that only the unbound bilirubin was
available as a substrate for HRP so that there was a linear
relationship between the rate of destruction of bilirubin and the
concentration of the unbound species.
Determination of advanced oxidation protein products
Advanced oxidation protein products (AOPP) levels were
determined spectrophotometrically by measuring the absorbance
of the samples at 340 nm and expressed as chloramine-T
equivalents after five-fold dilution of 200 mL of plasma with
20 mmol/L of pH 7.4 phosphate-buffered saline (PBS) and the
subsequent addition of 80 mL of acetic acid, and reading against a
blank PBS solution [26].
Statistical analysis
All data were expressed as the mean 6 SD. Differences between
groups were examined for statistical significance using the
Wilcoxon signed-rank test with Bonferroni correction, and the
magnitude of each correlation were evaluated using Spearman
rank-correlation coefficient. A P-value ,0.05 denoted the
presence of a statistically significant difference. The StatView 5.0
software was used for data analysis.
Results
Detection of Cys-Cys34-HSA in patients with chronic liver
disease by ESI-TOFMS
Two major peaks, corresponding to Cys-Cys34-HSA and
reduced Cys34-HSA, so-called HMA, were identified when
plasma samples obtained from healthy subjects were analyzed
by ESI-TOFMS (Figure 2A). We previously evaluated the
reproducibility of the redox state of Cys34 measurement in
human plasma. As a result, Cys-Cys34-HSA had high reproduc-
ibility values with a CV% of below 0.5% (intra-day, n = 4) and
1.55% (inter-day, n = 4) [18]. In agreement with previous
findings, an increased Cys-Cys34-HSA peak accompanied by a
decreased HMA peak was observed in patients with diabetes
mellitus or chronic renal failure (data not shown) [19,27]. Similar
changes in the HSA mass spectra (MS) profile were also found for
patients with chronic liver disease (Figure 2B). The HSA MS
profile of chronic liver disease after dithiothreitol (DTT)
treatment (Figure 2C) was similar to that for HSA profiles of
healthy subjects (Figure 2A), indicating that the DTT treatment
resulted in a reversal of the peaks for Cys-Cys34-HSA and HMA.
These results confirm that the oxidative modification of Cys34
that occur in chronic liver disease patients are largely a reversible
reaction, and that the most common oxidized form of Cys34 is
cysteinylation.
Correlation between Cys-Cys34-HSA and oxidized Cys34-
HSA
The degree of oxidized Cys34-HSA and the Cys-Cys34-HSA
fraction of plasma samples obtained from 229 patients with
chronic disease (including 139 patients with liver disease, 38
patients with kidney disease and 52 patients with diabetes
mellitus) was determined by HPLC and ESI-TOFMS respec-
tively and the correlation between these two parameters was
examined. As shown in Figure 3, a significant correlation was
observed between the fraction of Cys-Cys34-HSA and the degree
of oxidized Cys34-HSA. A significant correlation was also
observed for each of the disease groups such as chronic liver
disease, chronic kidney disease and diabetes mellitus (data not
shown).
Effect of disease severity or BCAA treatment on the Cys-
Cys34-HSA fraction in patients with chronic liver disease
The relationship between the Cys-Cys34-HSA fraction and
Child-Pugh classification in patients with chronic liver disease was
examined. As shown in Figure 4, an increase in the severity of the
disease was associated with an increase in the fraction of Cys-
Cys34-HSA, suggesting an association between the progression of
chronic liver disease and oxidative stress.
The effect of BCAA treatment on the Cys-Cys34-HSA
fraction in patients with chronic liver disease was examined.
As shown in Figure 5A, the Cys-Cys34-HSA fraction was
decreased as the result of the BCAA treatment, with a
significant improvement compared to the pre-treatment level
observed 5 months after the treatment. Figure 5B shows the
effect of BCAA treatment on plasma AOPP levels, a marker of
oxidative stress for proteins in patients with chronic liver
disease. The plasma AOPP levels were also decreased as the
result of the BCAA treatment at 5 months after the treatment
(Figure 5B). The Cys-Cys34-HSA fraction was significantly
correlated with plasma AOPP levels (Figure 5C), further
supporting the conclusion that the Cys-Cys34-HSA fraction is,
in fact, an appropriate marker for oxidative stress in the general
circulation.
Cys34-HSA fraction and the unbound fraction of warfarin (I), bilirubin (J), diazepam (K) and L-tryptophan (L) to purified HSA in chronic liver disease.
Values are expressed as mean 6 SD. *P,0.01 as compared with healthy subjects, #P,0.05 as compared with before treatment.
doi:10.1371/journal.pone.0085216.g006
ESI-TOFMS Quantification of Cysteinylated HSA
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Effect of the cysteinylation of Cys34 on ligand binding
ability of HSA purified from the plasma of chronic liver
disease patients
HSA has two major ligand bindings sites, so-called Site I and
Site II where localized in subdomain IIA and IIIA on HSA,
respectively (Figure 1). To investigate the effect of cysteinylation on
ligand binding property, binding experiments by ultrafiltration
technique were carried out using endogenous and exogenous
substances. Bilirubin and L-tryptophan, which preferentially bind
to Site I and Site II, respectively, were selected as models for
endogenous ligands related to liver disease. On the other hand,
warfarin and diazepam, representative drugs that bind to Site I
and Site II respectively, were used as exogenous ligands.
As reported previously, the HSA purified from the patients
showed an increased unbound fraction for all four ligands
compared to HSA purified from healthy subjects. As shown in
Figure 6A–D, the increases in the unbound fraction of all of the
four ligands were associated with the progression of liver disease.
In contrast, as shown in Figure 6E–H, the decreases in the
unbound fraction of all of the four ligands observed in patients
with chronic liver disease were significantly improved by the
BCAA treatment. Interestingly, a moderate correlation was
observed for the unbound fraction of warfarin and diazepam
and a causal relationship was shown in the case of the unbound
fraction of bilirubin and L-tryptophan with the Cys-Cys34-HSA
fraction (Figure 6I–L), suggesting that, the cysteinylation of Cys34
affected the microenvironment of the ligand binding sites.
Discussion
Oxidative stress may cause the reversible and/or irreversible
modification of sensitive proteins [17,21,28,29]. Since the redox
status of a free thiol group in proteins can be a very important
indicator of oxidative stress, determining the redox status of Cys34
in HSA may allow the degree of organ damage by oxidative stress
and the development of new anti oxidative therapeutic approach-
es. The utility of monitoring the redox status of Cys34 in HSA as a
marker for oxidative stress in the circulation was demonstrated in a
previous study by determining the degree of oxidized Cys34-HSA
by HPLC [30].
However, in order to be able to examine alterations in the
function of albumin by conventional procedures, the protein must
be purified from at least several mL of plasma which may not be
feasible in routine laboratory tests. Therefore, an analytical
method that requires only a small amount of plasma under a
clinical setting for the rapid measurement of the marker would be
desirable. Compared to HPLC, ESI-TOFMS is a high throughput
method that can be used to analyze large numbers of samples
rapidly and sensitively, and thus may be suitable for use in clinical
laboratory testing. Furthermore, the ESI-TOFMS method offers
an additional advantage of having the capability of characterizing
the different forms of Cys34 oxidized forms of Cys34 that are
produced by oxidation by a variety of endogenous substances.
Using ESI-TOFMS, the present study provides evidence that
the most common oxidized form is cysteinylated Cys34 (Figure 2B).
As shown in Figure 3, a significant positive correlation with a slope
of nearly 1 was observed between the degree of oxidized Cys34-
HSA estimated by HPLC and the fraction of Cys-Cys34-HSA
determined by ESI-TOFMS. These results suggest that the
fraction of Cys-Cys34-HSA is a more sensitive marker for
oxidative stress in plasma, than the degree of oxidized Cys34-
HSA determined by HPLC. The present study is the first to show
a marked oxidation, predominantly cysteinylation, of Cys34 in
oxidative stress-related diseases such as chronic liver and kidney
diseases and diabetes mellitus. The present study also found that
the Cys-Cys34-HSA fraction increased in proportion to the Child-
Pugh classification of cirrhotic patients. This is in agreement with
the findings that oxidative stress plays an important role in the
progression of chronic liver disease.
Recent studies have shown that the functional loss of HSA due
to post-translational modification could influence homeostasis,
which may contribute to the progression of chronic disease. Jalan
et al. proposed that the loss of ligand binding capacity of albumin
may be associated with an increased mortality of patients with
decompensated cirrhosis [31]. Very recently, Oettl et al. reported
that, in advanced liver disease, oxidative damage impairs the
binding properties of HSA [32]. This reduced binding capacity of
HSA is mainly related to impaired liver function. The decreased
binding of toxic endogenous compounds to HSA may result in
increased tissue distribution of these toxins, possibly enhancing the
risk of tissue damage related to complications. In this study, a
decreased binding affinity of bilirubin and tryptophan that might
be related to liver disease was observed with increasing severity of
liver disease. The present findings can be extrapolated to predict
the binding of bile acids, another endogenous substance associated
with disease progression, in chronic liver disease because bile acids
bind Site I or Site II [33].
Interestingly, the changes in ligand binding were correlated with
the alterations in the Cys-Cys34-HSA fraction. It is possible that
the cysteinylation of Cys34 caused the changes in the microen-
vironment of the ligand binding sites, especially Site II, which
could result in decreased ligand binding. On the other hand, the
cysteinylation of Cys34 may further induce oxidative modifications
to other amino acid residues that play an important role in ligand
binding [17,21]. Our previous in vitro examination showed that
the cysteinylation of Cys34 could induce structural changes in the
regions surrounding ligand binding sites [17]. Meanwhile, an
increased cysteinylation of Cys34 was found to be accompanied by
an increase in the carbonyl content of HSA [9], suggesting that
other residues in addition to Cys34, especially arginine, lysine,
histidine, tyrosine and tryptophan that significantly contribute to
ligand binding to Site I and Site II are oxidized. In fact, we
previously demonstrated that oxidative stress modified residues
Lys195, Lys190, Arg218, Trp211 and Arg222 that are involved in
the ligand binding to Site I, and Arg410 and Tyr411 residues,
which play a crucial role in the binding of ligands to Site II [12].
Thus, both direct and indirect mechanisms appear to be
responsible for the impaired ligand bindings accompanied with
cysteinylation of Cys34.
BCAA treatment improves hypoalbuminemia in chronic liver
disease patients by increasing the biosynthesis of HSA [34]. Recent
studies have revealed that this effect is mediated by the activation
of the mTOR pathway [35,36]. The findings of this study indicate
that the fraction of Cys-Cys34-HSA was significantly improved by
BCAA treatment, most likely due to the increased biosynthesis of
HMA. In addition to this indirect mechanism, recent studies have
also demonstrated that BCAA per se has antioxidant activity [37].
It is thus possible that a reduction of oxidative stress caused by
BCAA treatment led to a corresponding reduction in the
cysteinylation of Cys34. On the other hand, the decreased binding
affinity to bilirubin and tryptophan was recovered by a BCAA
treatment, which is likely to be the result of an increased
concentration of reduced Cys34 resulting from increased biosyn-
thesis. Since the loss of ligand binding properties of HSA against
these endogenous substances might contribute to an acceleration
or inhibition of disease progression, the correlation between the
Cys-Cys34-HSA fraction and the fraction of ligand binding to
HSA suggests that the Cys-Cys34-HSA fraction might also serve as
ESI-TOFMS Quantification of Cysteinylated HSA
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a marker for estimating changes in the physiological functions of
albumin.
Recent studies revealed that albumin is an antioxidant in
plasma and plays an important role in the homeostasis of the
intravascular environment. Terawaki et al. reported that a low
concentration of albumin with reduced Cys34 is associated with an
increased incidence of severe cardiovascular disorders in dialysis
patients due to a decreased antioxidative capacity [38]. This is
because antioxidants are not as abundant in the plasma as they are
in the cell, and albumin, which is abundant in plasma, serves as a
dominant antioxidant in plasma. This is supported by the fact that
about 80% of the total SH groups, a powerful ROS scavenger,
present in plasma originate from Cys34 [15]. In a previous study,
we reported that Cys34 accounted for approximately 40% of the
total radical scavenging activity of HSA [39,40]. Thus, the
observed changes in the Cys-Cys34-HSA fraction with increasing
severity of liver disease or BCAA treatment are likely to reflect an
alternation in available SH groups resulting from the cyteinylation
or de-cysteinylation of Cys34. Such changes in the cysteinylation
of Cys34 could influence to the antioxidative capacity in general
circulation, which may contribute to the progression of chronic
disease.
Conclusion
Cys-Cys34-HSA is a useful marker for estimating binding
properties of HSA and monitoring oxidative stress in the plasma of
chronic oxidative stress-related disease patients and ESI-TOFMS
can be used in clinical laboratory testing.
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